Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Similares en SciELO
Compartir
Revista alergia México
versión On-line ISSN 2448-9190
Resumen
MORALES-MUNERA, Olga; PEDRAZA, Ángela y NINO-SERNA, Laura. Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia. Rev. alerg. Méx. [online]. 2018, vol.65, n.3, pp.222-232. ISSN 2448-9190. https://doi.org/10.29262/ram.v65i3.510.
Background:
Omalizumab efficacy and safety in children older than 6 years has been clearly demonstrated in controlled clinical trials, but only in few real-life studies.
Objective: To assess the response with omalizumab addition in children with moderate to severe persistent asthma in real-life conditions.
Method:
Observational study with a 12-month real-life follow-up in a group of 61 children older than 6 years who were assessed for asthma control before treatment was started and at 4 and 12 months.
Results:
After 12 months of treatment with omalizumab, there was symptom improvement both for those younger and older than 12 years (p = 0.001). There was a decrease in controller drug consumption in 73% of patients; in 61%, inhaled corticosteroid dose was reduced, and 8% discontinued its use. Inhaled corticosteroid average dose was decreased to 396 ± 298 µg, with this being statistically significant (p = 0.02).
Conclusion:
Omalizumab is an efficacious, safe and well-tolerated drug as add-on therapy for clinical control of moderate and severe allergic asthma that has not improved with standard therapies.
Palabras llave : Omalizumab; Asthma; Child; Adolescent; Observational study.